Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
PhaseBio Pharmaceuticals, Inc. is a biotechnology company focused on developing novel therapies for rare diseases, particularly in the area of metabolic disorders. The company has a competitive edge through its proprietary technology platform, which enables the development of biologics that are more effective and have fewer side effects than traditional treatments.
PhaseBio's business model relies on developing and commercializing therapies for rare diseases. The company aims to leverage its proprietary technology to create unique biologics that can command premium pricing due to their specialized nature. However, with no current revenue, the focus is on securing partnerships and funding to support R&D efforts.
FDA approval of new therapies, particularly for its lead candidate, PB2452
Partnership announcements with larger pharmaceutical companies for co-development
Clinical trial results that demonstrate efficacy and safety
Market sentiment regarding the biotechnology sector
Regulatory changes that could impact drug approval processes
Technological disruption in biotechnology that could render current approaches obsolete
Emergence of alternative therapies from competitors targeting the same rare diseases
Potential for larger pharmaceutical companies to outspend PhaseBio in R&D
High cash burn rate with no current revenue, leading to potential liquidity issues
Dependence on external funding sources to sustain operations
low - The demand for rare disease treatments is less sensitive to economic cycles, as these therapies often address unmet medical needs regardless of broader economic conditions.
Moderate - Rising interest rates could increase the cost of capital for PhaseBio, impacting its ability to finance R&D activities. However, the company is not heavily reliant on debt.
minimal - The company has a negative debt/equity ratio, indicating low reliance on credit.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has exhibited significant volatility, particularly given its recent performance and lack of revenue.